Biotech 2050 Podcast

Steve Tregay on Leading Mission BioCapital as Managing Partner & Fueling Early-Stage Biotech


Listen Later

Synopsis:
Building in biotech isn’t for the faint of heart—especially during a market downturn.
But that’s exactly when Steve Tregay, Managing Partner at Mission BioCapital, thrives. A seasoned entrepreneur and founder of Forma Therapeutics, Steven has navigated biotech’s toughest cycles—and emerged stronger each time.
Hosted by Rahul Chaturvedi, this conversation dives into what it really takes to launch and scale biotech companies: from mastering the evolution of the CEO role to raising nearly $900M through strategic partnerships, to knowing when it’s time to pass the torch.
Steve also shares how Mission BioCapital is rewriting the playbook for early-stage innovation through its Platinum Program, offering $500K and lab access to science founders ready to launch bold new ideas.
Real talk, real strategies, and a blueprint for building lasting biotech companies—especially when its hardest.
Biography:
Steve Tregay, PhD is a Managing General Partner based in our Cambridge office. He focuses on new therapeutics investments with a particular emphasis on company creation opportunities as well as on overall management of the firm. Within the Mission BioCapital portfolio, he is currently founding CEO and board member of Arclight Therapeutics, LLC, a founding board member at Jupiter BioVentures LLC, and has board roles at Vedere Bio and Nocion Therapeutics. In addition, Steve serves as Chairman of the Board of Directors at LabCentral. He is a Harvard Blavatnik Biomedical Accelerator Advisory Committee member and is a member of the board of advisors for the non-profit Life Sciences Cares.
Previously, Steve was the Founder and CEO of FORMA Therapeutics. Additional roles held prior to his engagement at FORMA include Managing Director for the Novartis Venture Fund and Executive Director & Head of Strategic Alliances for Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. Prior to Novartis, he held roles in research and business development at Array BioPharma.
Steve received his doctoral and Master’s degrees in organic chemistry from Harvard University and a Bachelor’s from Davidson College.
...more
View all episodesView all episodes
Download on the App Store

Biotech 2050 PodcastBy Biotech 2050

  • 4.7
  • 4.7
  • 4.7
  • 4.7
  • 4.7

4.7

59 ratings


More shows like Biotech 2050 Podcast

View all
WSJ Your Money Briefing by The Wall Street Journal

WSJ Your Money Briefing

1,756 Listeners

Exchanges by Goldman Sachs

Exchanges

992 Listeners

The Knowledge Project with Shane Parrish by Shane Parrish

The Knowledge Project with Shane Parrish

2,648 Listeners

Odd Lots by Bloomberg

Odd Lots

1,796 Listeners

Masters of Scale by WaitWhat

Masters of Scale

4,000 Listeners

The Long Run with Luke Timmerman by Timmerman Report

The Long Run with Luke Timmerman

122 Listeners

The Readout Loud by STAT

The Readout Loud

318 Listeners

The Intrinsic Value Podcast - The Investor’s Podcast Network by The Investor's Podcast Network

The Intrinsic Value Podcast - The Investor’s Podcast Network

563 Listeners

Business Of Biotech by Ben Comer

Business Of Biotech

88 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

29 Listeners

Raising Health by Andreessen Horowitz, a16z Bio + Health

Raising Health

147 Listeners

Business Breakdowns by Colossus | Investing & Business Podcasts

Business Breakdowns

353 Listeners

Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

Biotech Hangout

18 Listeners

The So What from BCG by Boston Consulting Group BCG

The So What from BCG

221 Listeners

HBR On Leadership by Harvard Business Review

HBR On Leadership

155 Listeners